[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP]. 2014

Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
Dept. of Surgery, Izumi Municipal Hospital.

We present a case of recurrent gastric cancer in which stable disease status was achieved for four months due to treatment with capecitabine/cisplatin (CDDP)after the failure of multiple anticancer drugs including S-1/CDDP. A 67-year-old man was diagnosed with multiple liver metastases one year after distal gastrectomy+D2 dissection for gastric cancer. S-1/CDDP was given as the first-line treatment, followed by paclitaxel (PTX), irinotecan (CPT-11), and docetaxel (DOC). The tumor in the anterior segment of the liver was resistant to all of these chemotherapies except for PTX, which is why the regimens were changed. However, this tumor shrank and achieved stable disease status for four months after capecitabine/CDDP therapy given as fifth-line treatment. Our case suggests that S-1 and capecitabine do not always exhibit cross-resistance. Therefore, capecitabine may be effective in S-1-pretreated patients, and vice versa.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010094 Oxonic Acid Antagonist of urate oxidase. Oteracil
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207

Related Publications

Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
October 2012, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
December 2010, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
November 2013, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
April 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
March 2008, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
February 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
November 2014, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
November 2014, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
November 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Takeshi Sunami, and Jun Tauchi, and Katsuya Sakashita, and Kiyotaka Yukimoto, and Ryugo Sawada, and Kazutsugu Sakamoto
November 2007, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!